Rezolute Reports $0.20 Q4 Loss Per Share, Missing Analyst Estimates

Key Facts

1Rezolute reported a GAAP EPS of -$0.20, missing analyst estimates by $0.05.

Rezolute reported a GAAP loss per share of $0.20 for the fourth fiscal quarter, missing analyst estimates by $0.05. Seeking Alpha reported that the biopharmaceutical company's performance fell short of the consensus expectation, which had projected a loss of $0.15 per share.

Cash, cash equivalents, and investments in marketable securities totaled $107.8 million as of June 30, 2026, down from $167.9 million on June 30, 2025. RZLT closed at $4.00 on September 23, 2026, with a daily range between $3.98 and $4.13.